The AHA joined by the Association of American Medical Colleges and America’s Essential Hospitals today will urge a federal court to prevent the Department of Health and Human Services from reducing Medicare payments under the 340B drug savings program by nearly 30% effective Jan. 1. In a brief to be filed today in reply to the agency’s motion to dismiss their lawsuit challenging the reduction, the hospital groups say the payment cut “far exceeds” HHS’s authority to adjust the reimbursement rate and warrants a preliminary injunction to prevent “imminent” and “actual” harm to their members. Thirty-two state and regional hospital associations also today will urge the court in a friend-of-the-court brief to grant the preliminary injunction, arguing that the estimated $1.6 billion cut “will have devastating consequences for safety-net providers and the millions of patients they serve.”

Related News Articles

Headline
The White House announced today that it reached agreements with Eli Lilly and Novo Nordisk to align their drug prices with the lowest paid by other developed…
Headline
The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model…
Headline
Cigna’s Evernorth division Oct. 27 announced a new, rebate-free pharmacy benefit model, beginning in 2027, that would reduce monthly prescription drug costs by…
Headline
The median net launch price for 154 new drugs increased 51% between 2022 and 2024, after accounting for inflation and discounts, according to a report released…
Headline
The Senate Committee on Health, Education, Labor and Pensions Oct. 23 held a hearing discussing the 340B Drug Pricing Program and its growth and impacts on…
Headline
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…